Application progress of mesenchymal stem cells in islet transplantation for type 1 diabetes mellitus
10.3969/j.issn.1674-7445.2023194
- VernacularTitle:间充质干细胞在1型糖尿病胰岛移植中的应用进展
- Author:
Shufang ZHU
1
;
Lisha MOU
2
,
3
Author Information
1. Guangxi University of Chinese Medicine, Nanning 530200, China.
2. Guangxi University of Chinese Medicine, Nanning 530200, China
3. .
- Publication Type:ExpertForum
- Keywords:
Mesenchymal stem cell;
Type 1 diabetes;
Islet transplantation;
Exosome;
Immune tolerance;
Angiogenesis;
Rejection;
Oxidative stress
- From:
Organ Transplantation
2024;15(2):214-219
- CountryChina
- Language:Chinese
-
Abstract:
Islet transplantation is considered as one of the most effective approach for type 1 diabetes mellitus, although its efficacy is limited by several factors. Anoxia, stress and rejection occurring during the isolation, culturing and transplantation of islets may have impact on the outcome of the islet transplantation. Due to the biological properties such as anti-inflammation, angiogenetic promotion and immune regulation, mesenchymal stem cells (MSCs) are all the way focused by researchers. Additionally, exosome, a derivative of MSC, also plays an import role in regulating anoxia-induced oxidative stress modulation, angiogenetic promotion, and immune regulation. MSC-based islet transplantation may be a useful therapeutic tool in treating type 1 diabetes. Therefore, in this review, the potential effect of MSC prior and posterior to the operation of the islet transplantation, its clinical application as well as its limitations were reviewed, aiming to offer insights into the future application of islet transplantation in treating type 1 diabetes.
